This study looks into treating a serious kidney problem called **Lupus Nephritis (LN)**, which is related to a disease called **Systemic Lupus Erythematosus (SLE)**. The study combines two drugs, **Belimumab (BEL)** and **Voclosporin (VCS)**, with another drug called **Mycophenolate Mofetil (MMF)** to see if more patients can get better. The goal is to improve kidney health and possibly reduce the use of MMF. In this study, doctors hope the new drug combination will help more patients achieve a complete renal response (CRR), which means their kidneys are working better. The study lasts for some time and involves taking these medications regularly. **Key Points:** - **Study Length:** Participating in the study requires commitment over a period, as it involves regular medication and monitoring. - **Eligibility:** Participants need to be between 18-80 years old, have a specific diagnosis of lupus nephritis, and meet other health criteria. - **Risks & Benefits:** There are potential risks from the medications, but also potential benefits if the kidney function improves significantly. Participants must be willing to follow the study's rules and attend regular medical check-ups.